# Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects

> **NCT02264054** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]talsaclidine, oral
- **DRUG:** [14C]talsaclidine, iv

## Key facts

- **NCT ID:** NCT02264054
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-02
- **Primary completion:** 1999-03
- **Final completion:** —
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02264054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02264054, "Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02264054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*